{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:06:31Z","timestamp":1761102391698},"reference-count":70,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2020,2,1]]},"DOI":"10.1001\/jamainternmed.2019.5161","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T15:32:23Z","timestamp":1572276743000},"page":"292","source":"Crossref","is-referenced-by-count":5,"title":["Confidentiality Orders and Public Interest in Drug and Medical Device Litigation"],"prefix":"10.1001","volume":"180","author":[{"given":"Alexander C.","family":"Egilman","sequence":"first","affiliation":[{"name":"Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut"},{"name":"Collaboration for Research Integrity and Transparency, Yale Law School, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital\/Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut"},{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"},{"name":"Section of General Internal Medicine and National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Associate Editor, JAMA Internal Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanie","family":"Kim","sequence":"additional","affiliation":[{"name":"Collaboration for Research Integrity and Transparency, Yale Law School, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Kapczynski","sequence":"additional","affiliation":[{"name":"Collaboration for Research Integrity and Transparency, Yale Law School, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"3","key":"isc190005r2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1001\/jama.297.3.308","article-title":"The role of litigation in defining drug risks.","volume":"297","author":"Kesselheim","year":"2007","journal-title":"JAMA"},{"issue":"4","key":"isc190005r3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.7326\/0003-4819-149-4-200808190-00006","article-title":"The ADVANTAGE seeding trial: a review of internal documents.","volume":"149","author":"Hill","year":"2008","journal-title":"Ann Intern Med"},{"issue":"15","key":"isc190005r4","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1001\/jama.299.15.1800","article-title":"Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.","volume":"299","author":"Ross","year":"2008","journal-title":"JAMA"},{"issue":"15","key":"isc190005r5","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1001\/jama.299.15.1813","article-title":"Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation.","volume":"299","author":"Psaty","year":"2008","journal-title":"JAMA"},{"issue":"21","key":"isc190005r6","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1001\/archinternmed.2009.394","article-title":"Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.","volume":"169","author":"Ross","year":"2009","journal-title":"Arch Intern Med"},{"issue":"1","key":"isc190005r7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/08989621.2017.1405259","article-title":"Grave fraudulence in medical device research: a narrative review of the PIN seeding study for the Pinnacle hip system.","volume":"25","author":"Steffen","year":"2018","journal-title":"Account Res"},{"issue":"1","key":"isc190005r12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2202\/1938-2545.1052","article-title":"Bring back Bentham: \u201copen courts,\u201d \u201cterror trials,\u201d and public sphere(s).","volume":"5","author":"Resnik","year":"2011","journal-title":"Law Ethics Hum Rights."},{"issue":"9","key":"isc190005r18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000335","article-title":"The haunting of medical journals: how ghostwriting sold \u201cHRT\u201d.","volume":"7","author":"Fugh-Berman","year":"2010","journal-title":"PLoS Med"},{"issue":"9","key":"isc190005r23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000156","article-title":"Ghostwriting: the dirty little secret of medical publishing that just got bigger.","volume":"6","author":"PLoS Medicine Editors","year":"2009","journal-title":"PLoS Med"},{"key":"isc190005r43","first-page":"565","article-title":"When the bell can\u2019t be unrung: document leaks and protective orders in mass tort litigation.","volume":"27","author":"Childs","year":"2007","journal-title":"Rev Litig"},{"issue":"1","key":"isc190005r50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3233\/JRS-160671","article-title":"The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance.","volume":"28","author":"Jureidini","year":"2016","journal-title":"Int J Risk Saf Med"},{"issue":"1","key":"isc190005r55","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.socscimed.2009.05.001","article-title":"The promotion of olanzapine in primary care: an examination of internal industry documents.","volume":"69","author":"Spielmans","year":"2009","journal-title":"Soc Sci Med"},{"issue":"7585","key":"isc190005r59","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/bmj.39024.487720.68","article-title":"What have we learnt from Vioxx?","volume":"334","author":"Krumholz","year":"2007","journal-title":"BMJ"},{"issue":"15","key":"isc190005r60","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1001\/jama.299.15.1833","article-title":"Impugning the integrity of medical science: the adverse effects of industry influence.","volume":"299","author":"DeAngelis","year":"2008","journal-title":"JAMA"},{"issue":"1","key":"isc190005r61","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1891\/ehpp.8.1.77","article-title":"Court filing makes public my previously suppressed analysis of Paxil\u2019s effects.","volume":"8","author":"Breggin","year":"2006","journal-title":"Ethical Hum Psychol Psychiatry"},{"issue":"2","key":"isc190005r63","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1891\/ehpp.8.2.91","article-title":"How GlaxoSmithKline suppressed data on Paxil-induced akathisia: implications for suicidality and violence.","volume":"8","author":"Breggin","year":"2006","journal-title":"Ethical Hum Psychol Psychiatry"},{"issue":"3","key":"isc190005r64","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1891\/ehppij-v8i3a008","article-title":"Drug company suppressed data on paroxetine-induced stimulation: implications for violence and suicide.","volume":"8","author":"Breggin","year":"2006","journal-title":"Ethical Hum Psychol Psychiatry"},{"key":"isc190005r13","volume-title":"Sealing Court Records and Proceedings: A Pocket Guide","author":"Reagan","year":"2010"},{"key":"isc190005r14","volume-title":"Confidential Discovery: A Pocket Guide on Protective Orders","author":"Reagan","year":"2012"},{"key":"isc190005r19"},{"key":"isc190005r20","year":"2009"},{"key":"isc190005r21"},{"key":"isc190005r24"},{"key":"isc190005r25"},{"key":"isc190005r26"},{"key":"isc190005r27"},{"key":"isc190005r35","year":"2018"},{"key":"isc190005r36","year":"2019"},{"key":"isc190005r37","year":"2016"},{"key":"isc190005r47"},{"key":"isc190005r51"},{"key":"isc190005r52"},{"key":"isc190005r53"},{"key":"isc190005r54","year":"2017."},{"key":"isc190005r58","year":"2018"},{"key":"isc190005r62","year":"2001"},{"key":"isc190005r67"},{"key":"isc190005r1","unstructured":"Twenty-seven years of pharmaceutical industry criminal and civil penalties: 1991 through 2017. Public Citizen. March 14, 2018. https:\/\/www.citizen.org\/article\/twenty-seven-years-of-pharmaceutical-industry-criminal-and-civil-penalties-1991-through-2017\/. Accessed September 19, 2019."},{"key":"isc190005r8","unstructured":"ArmstrongD. Secret trove reveals bold \u2018crusade\u2019 to make OxyContin a blockbuster. Stat News. September 22, 2016. https:\/\/www.statnews.com\/2016\/09\/22\/abbott-oxycontin-crusade\/. Accessed September 19, 2019."},{"key":"isc190005r9","unstructured":"JosephA. Judge orders full release of redacted lawsuit against Purdue Pharma, maker of OxyContin. Stat News. January 28, 2019. https:\/\/www.statnews.com\/2019\/01\/28\/judge-order-full-release-purdue-pharma-lawsuit\/. Accessed September 19, 2019."},{"key":"isc190005r10","unstructured":"GilG. What you should know about Richard Sackler\u2019s long-sought deposition. ProPublica. February 21, 2019. https:\/\/www.propublica.org\/article\/what-you-should-know-about-richard-sacklers-long-sought-deposition. Accessed September 19, 2019."},{"key":"isc190005r11","unstructured":"JosephA. Purdue appeals order to unseal OxyContin records to Kentucky Supreme Court. Stat News. January 14, 2019. https:\/\/www.statnews.com\/2019\/01\/14\/purdue-pharma-appeal-kentucky-supreme-court\/. Accessed September 19, 2019."},{"key":"isc190005r15","unstructured":"Drug Industry Documents Archive. University of California San Francisco Library. https:\/\/www.industrydocumentslibrary.ucsf.edu\/drug\/about\/overview\/. Accessed September 19, 2019."},{"key":"isc190005r16","unstructured":"Federal Rules of Civil Procedure. Washington, DC: US Government Publishing Office; December 1, 2018. https:\/\/www.uscourts.gov\/sites\/default\/files\/cv_rules_eff._dec._1_2018_0.pdf. Accessed September 19, 2019."},{"key":"isc190005r17","unstructured":"KolataG, PetersenM. Hormone replacement study: a shock to the medical system. The New York Times. July 10, 2002. https:\/\/www.nytimes.com\/2002\/07\/10\/us\/hormone-replacement-study-a-shock-to-the-medical-system.html. Accessed September 19, 2019."},{"key":"isc190005r22","unstructured":"SingerN. Medical papers by ghostwriters pushed therapy. The New York Times. August 4, 2009. https:\/\/www.nytimes.com\/2009\/08\/05\/health\/research\/05ghost.html. Accessed September 19, 2019."},{"key":"isc190005r28","unstructured":"LesserB, LevineD, GirionL, DowdellJ. How judges added to the grim toll of opioids. Reuters. June 25, 2019. https:\/\/www.reuters.com\/investigates\/special-report\/usa-courts-secrecy-judges\/#graphic-litigation. Accessed September 19, 2019."},{"key":"isc190005r29","unstructured":"EschC. How one sentence helped set off the opioid crisis. Marketplace. December 13, 2017. https:\/\/www.marketplace.org\/2017\/12\/13\/health-care\/uncertain-hour\/opioid. Accessed September 19, 2019."},{"key":"isc190005r30","unstructured":"RyanH, GirionL, GloverS. More than 1 million OxyContin pills ended up in the hands of criminals and addicts: what the drugmaker knew. The Los Angeles Times. July 10, 2016. http:\/\/www.latimes.com\/projects\/la-me-oxycontin-part2\/. Accessed September 19, 2019."},{"key":"isc190005r31","unstructured":"ArmstrongD. Document: facing blame for seeding the opioid crisis, Purdue explored its next profit opportunity \u2013 treating addiction. Stat News. January 30, 2019. https:\/\/www.statnews.com\/2019\/01\/30\/purdue-pharma-oxycontin-maker-explored-addiction-treatment\/. Accessed September 19, 2019."},{"key":"isc190005r32","unstructured":"ArmstrongD. Sackler embraced plan to conceal OxyContin\u2019s strength from doctors, sealed testimony shows. ProPublica. February 21, 2019. https:\/\/www.propublica.org\/article\/richard-sackler-oxycontin-oxycodone-strength-conceal-from-doctors-sealed-testimony. Accessed September 19, 2019."},{"key":"isc190005r33","unstructured":"RyanH, GirionL, GloverS. \u201cYou want a description of hell?\u201d OxyContin\u2019s 12-hour problem. The Los Angeles Times. May 5, 2016. http:\/\/www.latimes.com\/projects\/oxycontin-part1\/. Accessed September 19, 2019."},{"key":"isc190005r34","unstructured":"ArmstrongD. STAT goes to court to unseal records of OxyContin maker. Stat News. March 15, 2016. https:\/\/www.statnews.com\/2016\/03\/15\/stat-seeks-oxycontin-records\/. Accessed September 19, 2019."},{"key":"isc190005r38","unstructured":"JosephA. STAT wins long legal fight as Kentucky Supreme Court clears way for release of Purdue OxyContin files. Stat News. August 26, 2019. https:\/\/www.statnews.com\/2019\/08\/26\/kentucky-supreme-court-allows-release-of-purdue-oxycontin-records\/. Accessed September 25, 2019."},{"key":"isc190005r39","unstructured":"ArmstrongD. Drug maker thwarted plan to limit OxyContin prescriptions at dawn of opioid epidemic. Stat News. October 26, 2016. https:\/\/www.statnews.com\/2016\/10\/26\/oxycontin-maker-thwarted-limits\/. Accessed July 24, 2019."},{"key":"isc190005r40","unstructured":"BerensonA. Eli Lilly said to play down risk of top pill. The New York Times. December 17, 2006. https:\/\/www.nytimes.com\/2006\/12\/17\/business\/17drug.html. Accessed July 24, 2019."},{"key":"isc190005r41","unstructured":"BerensonA. Drug files show maker promoted unapproved use. The New York Times. December 18, 2006. https:\/\/www.nytimes.com\/2006\/12\/18\/business\/18drug.html. Accessed July 24, 2019."},{"key":"isc190005r42","unstructured":"In re Zyprexa Injunction, 474 F Supp 2d 385 (US District Court for the Eastern District of New York). February 13, 2007. https:\/\/casetext.com\/case\/in-re-zyprexa-injunction. Accessed July 24, 2019."},{"key":"isc190005r44","unstructured":"BerensonA. Lilly to pay $690 million in drug suits. The New York Times. June 10, 2005. https:\/\/www.nytimes.com\/2005\/06\/10\/business\/lilly-to-pay-690-million-in-drug-suits.html. Accessed July 24, 2019."},{"key":"isc190005r45","unstructured":"BerensonA. Lilly settles with 18,000 over Zyprexa. The New York Times. January 5, 2007. https:\/\/www.nytimes.com\/2007\/01\/05\/business\/05drug.html. Accessed July 24, 2019."},{"key":"isc190005r46","unstructured":"PringleE. Eli Lilly the habitual offender. Lawyers and Settlements. January 25, 2007. https:\/\/www.lawyersandsettlements.com\/articles\/drugs-medical\/zyprexa-misconduct-00567.html. Accessed September 25, 2019."},{"key":"isc190005r48","unstructured":"Doctor Who Leaked Documents Will Pay $100,000 to Lilly. The New York Times. September 8, 2007. https:\/\/www.nytimes.com\/2007\/09\/08\/business\/08lilly.html. Accessed July 24, 2019."},{"key":"isc190005r49","unstructured":"BerensonA. Lilly adds strong warning label to Zyprexa, a schizophrenia drug. The New York Times. October 6, 2007. https:\/\/www.nytimes.com\/2007\/10\/06\/business\/06zyprexa.html. Accessed July 24, 2019."},{"key":"isc190005r56","unstructured":"PostonB. Capping years of criticism, Purdue Pharma will stop promoting its opioid drugs to doctors. The Los Angeles Times. February 10, 2018. https:\/\/www.latimes.com\/local\/lanow\/la-me-ln-purdue-marketing-20180210-story.html. Accessed July 24, 2019."},{"key":"isc190005r57","unstructured":"SilvermanE. Merck seeks sanctions against expert witness for talking to a journalist. Wall Street Journal. June 16, 2014. https:\/\/blogs.wsj.com\/pharmalot\/2014\/06\/16\/merck-seeks-sanctions-against-expert-witness-for-talking-to-a-journalist\/. Accessed July 24, 2019."},{"key":"isc190005r65","unstructured":"Stipulated protective order for standard litigation. United States District Court Northern District of California. https:\/\/www.cand.uscourts.gov\/model-protective-orders. Accessed September 25, 2019."},{"key":"isc190005r66","unstructured":"CRIT releases report on opposing secrecy in medical product litigation.YLS Today. https:\/\/law.yale.edu\/yls-today\/news\/crit-releases-report-opposing-secrecy-medical-product-litigation. Accessed September 25, 2019."},{"key":"isc190005r68","unstructured":"Texas Rules of Civil Procedure. Rule 76a(1)(a)(2). http:\/\/www.txcourts.gov\/media\/1055394\/trcp-20150901.pdf. Accessed September 25, 2019."},{"key":"isc190005r69","unstructured":"Local Civil Rules for the United States District Court. District of South Carolina. January 2012. http:\/\/www.scd.uscourts.gov\/Rules\/2012\/CivRules_Jan12.pdf. Accessed September 25, 2019."},{"key":"isc190005r70","unstructured":"Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA activities related to the ongoing post-market review of Essure and FDA\u2019s commitment to keep women informed [press release]. Washington, DC: Food and Drug Administration; March 7, 2018. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm600052.htm. Accessed September 25, 2019."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2753427\/jamainternal_egilman_2019_sc_190005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T16:02:07Z","timestamp":1580745727000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2753427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2019.5161","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}